ONC
BeOne Medicines Ltd. American Depositary Shares
Â
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Employees: 11,000
0
Funds holding %
of 7,321 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
158% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 26
50% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 9 (+3) [Q1 2025]
43% more capital invested
Capital invested by funds: $8.06B [Q4 2024] → $11.6B (+$3.5B) [Q1 2025]
16% more funds holding
Funds holding: 223 [Q4 2024] → 259 (+36) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 75
3% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $42.9M
0.18% less ownership
Funds ownership: 3.49% [Q4 2024] → 3.31% (-0.18%) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$311
6%
upside
Avg. target
$337
14%
upside
High target
$350
19%
upside
6 analyst ratings
6Â positive
100%
0Â neutral
0%
0Â negative
0%
JP Morgan Jessica Fye | 17%upside $345 | Overweight Maintained | 17 Jul 2025 |
RBC Capital Leonid Timashev | 18%upside $349 | Outperform Maintained | 16 Jul 2025 |
Morgan Stanley Sean Laaman | 12%upside $330 | Overweight Maintained | 27 Jun 2025 |
RBC Capital Gregory Renza | 6%upside $311 | Outperform Maintained | 8 May 2025 |
Guggenheim Michael Schmidt | 19%upside $350 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 9 articles about ONC published over the past 30 days
Positive
Investors Business Daily
1 day ago
The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs
Rambus stock hit a 52-week high and is in the buy zone of a cup-with-handle base.
Positive
Zacks Investment Research
1 day ago
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
BeOne Medicines Ltd. - Sponsored ADR (ONC) witnessed a jump in share price last session on above-average trading volume.
Neutral
Investors Business Daily
3 days ago
Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock
This cancer treatment stock is nearing a buy point of a base. Shares have already gained 50% so far this year.
Neutral
Business Wire
3 days ago
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hke.
Neutral
Business Wire
1 week ago
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasop.
Neutral
Business Wire
1 week ago
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen's RenMice® ful.
Neutral
Business Wire
1 week ago
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING--(BUSINESS WIRE)-- #Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen's RenMice® ful.
Neutral
Business Wire
3 weeks ago
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. “At BeOne, our mission is simple yet bold: to create t.
Neutral
Business Wire
3 weeks ago
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
BASEL, Switzerland--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. The CHMP positive opinion will now be reviewed by the European Commission, which will grant the marketing authoriza.
Positive
Seeking Alpha
1 month ago
BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium
BEIGF recently rebranded to BeOne Medicines and relocated to Switzerland. It now operates a worldwide R&D and sales footprint across major oncology markets. Its main value driver is Brukinsa which accounts for 72% of their Q1 2025 revenues. There are continued label expansions planned as well. Tevimbra is its second growth engine, and BEIGF has full global rights outside China.
Charts implemented using Lightweight Charts™